In vivo neurochemistry with emission tomography and magnetic resonance spectroscopy: Clinical applications

European Radiology

Volumn 12, Issue 10, 2002, Pages 2582-2599

  Del Sole, Angelo ^a   Gambini, Anna ^b   Falini, Andrea ^b   Lecchi, Michela ^c   Lucignani, Giovanni ^c,d  

^a SAN PAOLO HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Alzheimer's disease; Epilepsy; MR spectroscopy; Neuroimaging; Neurotransmitters; Parkinson's disease; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; NEUROTRANSMITTER; OXYGEN;

BLOOD FLOW; CEREBROVASCULAR DISEASE; CLINICAL RESEARCH; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONCENTRATION (PARAMETERS); DEGENERATIVE DISEASE; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EPILEPSY; GLUCOSE METABOLISM; HUMAN; HYDROGENATION; IMAGE ANALYSIS; IN VIVO STUDY; INTERMETHOD COMPARISON; MEDICAL INFORMATION; MEDICAL SPECIALIST; METHODOLOGY; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; BRAIN DISEASE; BRAIN LEVEL; SCINTISCANNING;

BRAIN CHEMISTRY; BRAIN DISEASES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036781030     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-002-1419-x     Document Type: Review

References (99)

1. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE (1979) Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 6:371-388
2. 15O and positron emission tomography: theory, procedure and normal values. J Comput Assist Tomogr 4:727-736
3. Wagner HNJ, Burns HD, Dannals RF, Wong DF, Langstrom B, Duelfer T, Frost JJ, Ravert HT, Links JM, Rosenbloom SB, Lukas SE, Kramer AV, Kuhar MJ (1983) Imaging dopamine receptors in the human brain by positron emission tomography. Science 221:1264-1266
4. Eckelman WC, Reba RC, Rzeszotarski WJ, Gibson RE, Hill T, Holman BL, Budinger T, Conklin JJ, Eng R, Grissom MP (1984) Cerebral imaging of acetylcholine muscarinic receptors. Science 223:291-293
5. Frey KA, Minoshima S, Kuhl DE (1998) Neurochemical imaging of Alzheimer's disease and other degenerative dementias. Q J Nucl Med 42:166-178
6. 18FDG PET. J Nucl Med 36:1238-1248
7. Miller BL, Ikonte C, Ponton M, Levy M, Boone K, Darby A, Berman N, Mena I, Cummings JL (1997) A study of the Lund-Manchester research criteria for frontotemporal dementia: clinical and single-photon emission CT correlations. Neurology 48:937-942
8. Albin RL, Minoshima S, D'Amato CJ, Frey KA, Kuhl DE, Sima AAF (1996) Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 47:462-466
9. 18F]FDG. J Nucl Med 35:210-216
10. Kuhl DE, Koeppe RA, Fessler JA, Minoshima S, Ackermann RJ, Carey JE, Glidersleeve DL, Frey KA, Wieland DM (1994) In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM. J Nucl Med 35:405-410
11. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, Wieland DM, Koeppe RA (1996) In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 40:399-410
12. Iyo M, Namba H, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Nagatsuka S, Sumara T, Sudo Y, Suzuki K, Irie T (1997) Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease. Lancet 349:1805-1809
13. 11C]tropanyl benzilate. J Cereb Blood Flow Metab 16:303-310
14. 11C]NMPB and PET. Synapse 39:275-287
15. Ohyama M, Senda M, Ishiwata K, Kitamura S, Mishina M, Ishii K, Toyama H, Oda K, Katayama Y (1999) Preserved benzodiazepine receptors in Alzheimer's disease measured with C-11 flumazenil PET and I-123 iomazenil SPECT in comparison with CBF. Ann Nucl Med 13:309-315
16. Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD (1995) Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195:65-72
17. Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW (1997) Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49:1513-1521
18. Ernst T, Chang L, Melchor R, Mehringer CM (1997) Frontotemporal dementia and early Alzheimer disease: differentiation with frontal lobe H-1 MR. Radiology 203:829-836
19. Oba H, Araki T, Ohtomo K, Monzawa S, Uchiyama G, Koizumi K, Nogata Y, Kachi K, Shiozawa Z, Kobayashi M (1993) Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 189:843-846
20. Segawa F (1993) MR findings of the pyramidal tract in amyotrophic lateral sclerosis. Rinsho Shinkeigaku - Clin Neurol 33:835-844
21. Drayer BP (1988) Imaging of the aging brain. II. Pathologic conditions. Radiology 166:797-806
22. Pioro EP, Antel JP, Cashman NR, Arnold DL (1994) Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 44:1933-1968
23. Gredal O, Rosenbaum S, Topp S, Karlsborg M, Strange P, Werdelin L (1997) Quantification of brain metabolites in amyotrophic lateral sclerosis by localized proton magnetic resonance spectroscopy. Neurology 48:878-881
24. Rooney WD, Miller RG, Gelinas D, Schuff N, Maudsley AA, Weiner MW (1998) Decreased N-acetylaspartate in motor cortex and corticospinal tract in ALS. Neurology 50:1800-1805
25. Ellis CM, Simmons A, Andrews C, Dawson JM, Williams SC, Leigh PN (1998) A proton magnetic resonance spectroscopic study in ALS: correlation with clinical findings. Neurology 51:1104-1109
26. Cwik VA, Hanstock CC, Allen PS, Martin WR (1998) Estimation of brainstem neuronal loss in amyotrophic lateral sclerosis with in vivo proton magnetic resonance spectroscopy. Neurology 50:72-77
27. Chan S, Shungu DC, Douglas-Akinwande A, Lange DJ, Rowland LP (1999) Motor neuron diseases: comparison of single-voxel proton MR spectroscopy of the motor cortex with MR imaging of the brain. Radiology 212:763-769
28. Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN (2000) Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 123:2289-2296
29. Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic-dependent cognitive deficits in Parkinson's disease. Ann Neurol 22:26-30
30. Hornykiewicz O, Kish SJ (1986) Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34
31. Baronti F, Conant KE, Giuffra M, Davis TL, Brughitta G, Iadarola M, Berrettini WH, Chase TN, Mouradian MM (1991) Opioid peptides in Parkinson's disease: effects of dopamine repletion. Brain Res 560:92-96
32. Perlmutter JS, Raichle ME (1985) Regional blood flow in hemiparkinsonism. Neurology 35:1127-1134
33. 18F-fluorodeoxyglucose method. Ann Neurol 15:419-424
34. Nahmias C, Garnett ES, Firnau G, Long A (1985) Striatal dopamine distribution in parkinsonian patients during life. J Neurol Sci 69:223-230
35. Martin WR, Palmer MR, Patlak CS, Calne DB (1989) Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol 26:535-542
36. 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 28:547-555
37. Brooks DJ, Salmon EP, Mathias CJ, Quinn N, Leenders KL, Bannister R, Marsden CD, Frackowiak RSJ (1990) The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain 113:1539-1552
38. 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 54:898-904
39. 123I] beta-CIT-SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 46:231-237
40. 11C-WIN 35,428 PET imaging of the dopamine transporter. J Nucl Med 36:99
41. 123I]β-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with SPET. Eur J Nucl Med 25:1270-1276
42. Nadeau SE, Couch MW, Devane CL, Shukla SS (1995) Regional analysis of D2 dopamine receptors in Parkinson's disease using SPECT and iodine-123-iodobenzamide. J Nucl Med 36:384-393
43. 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun 15:806-813
44. Rinne JO, Laihinen A, Nagren K, Bergman J, Ruotsalainen U, Rinne UK (1990) PET demonstrates different behaviour of striatal dopamine D-1 and D-2 receptors in early Parkinson's disease. J Neurosci Res 27:494-499
45. 11C-N-methyl-spiperone. Acta Neurol Scand 75:87-94
46. 11C]-raclopride. Mov Disord 12:33-38
47. 123I-IBZM single photon emission computed tomography. Arch Neurol 50:513-516
48. Buck A, Westera G, Sutter M, Albani C, Kung HF, Schulthess GKJ von (1995) Iodine-123-IBF SPECT evaluation of extrapyramidal diseases. J Nucl Med 36:1196-1200
49. 11C-raclopride and positron emission tomography. Ann Neurol 31:184-192
50. National Institute of Neurological Disease and Stroke rt-PA Study Group (1995) Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 355:1581-1587
51. 123I-Iomazenil SPECT. J Nucl Med 36:2154-2161
52. Ricci PE (1998) Proton MR spectroscopy in ischemic stroke and other vascular disorders. Neuroimaging Clin North Am 8:881-900
53. Monsein LH, Mathews VP, Barker PB, Pardo CA, Blackband SJ, Whitlow WD, Wong DF, Bryan RN (1993) Irreversible regional cerebral ischemia: serial MR imaging and proton MR spectroscopy in a nonhuman primate model. Am J Neuroradiol 14:963-970
54. Gillard JH, Barker PB, van Zijl PC, Bryan RN, Oppenheimer SM (1996) Proton MR spectroscopy in acute middle cerebral artery stroke. Am J Neuroradiol 17:873-886
55. Beauchamp NJ, Barker PB, Wang PY, van Zijl PC (1999) Imaging of acute cerebral ischemia. Radiology 212:307-324
56. Barker PB, Gillard JH, van Zijl PC, Sober BJ, Hanley DF, Agildere AM, Oppenheimer SM, Bryan RN (1994) Acute stroke: evaluation with serial proton MR spectroscopic imaging. Radiology 192:723-732
57. Sager TN, Laursen H, Hansen AJ (1995) Changes in N-acetyl-aspartate content during focal and global brain ischemia of the rat. J Cereb Blood Flow Metab 15:639-646
58. Duijn JH, Matson GB, Maudsley AA, Hugg JW, Weiner MW (1992) Human brain infarction: proton MR spectroscopy. Radiology 183:711-718
59. Graham GD, Blamire AM, Rothman DL, Brass LM, Fayad PB, Petroff OA, Prichard JW (1993) Early temporal variation of cerebral metabolites after human stroke. Stroke 24:1891-1896
60. Graham GD, Kalvach P, Blamire AM, Brass LM, Fayad PB, Prichard JW (1995) Clinical correlates of proton magnetic resonance spectroscopy findings after acute cerebral infarction. Stroke 26:225-229
61. Federico F, Simone IL, Conte C, Lucivero V, Giannini P, Liguori M, Picciola E, Tortorella C (1996) Prognostic significance of metabolic changes detected by proton MRS in ischaemic stroke. J Neurol 243:241-247
62. Parsons MW, Li T, Barber PA, Yang Q, Darby DG, Desmond PM, Gerraty RP, Tress BM, Davis SM (2000) Combined (1)H MR spectroscopy and diffusion-weighted MRI improves the prediction of stroke outcome. Neurology 55:498-505
63. Felber SR, Luef G, Aichner FT (1992) 1-H-localized magnetic resonance spectroscopy: preliminary observations in transient ischemic attacks. J Neurol Sci 108:35-38
64. Giroud M, Walker P, Guy F, Lemesle M, Lalande A, Baudouin N, Martin D, Couveur G, Brunotte (1999) Cerebral metabolism after transient ischemic attack. A 1H MR spectroscopy study. Neurol Res 21:563-565
65. Engel J Jr, Kuhl DE, Phelps ME (1982) Patterns of human local cerebral glucose metabolism during epileptic seizures. Science 218:64-66
66. 18F-fluorodoxyglucose positron emission tomography in refractory complex partial seizures. Ann Neurol 14:429-437
67. Abou-Khalil BW, Siegel GJ, Sackellares JC, Gilman S, Hichwa R, Marshall R (1989) Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy. Ann Neurol 22:480-486
68. Henry TR, Mazziotta JC, Engel J Jr, Christenson PD, Zhang JX, Phelps ME, Kuhl DE (1990) Quantifying interictal metabolic activity in human temporal lobe epilepsy. J Cereb Blood Flow Metab 10:748-757
69. Theodore WH, Fishbein D, Dubinsky R (1988) Patterns of cerebral glucose metabolism in patients with partial seizures. Neurology 38:1201-1206
70. 18F-FDG positron emission tomography. Neurology 43:79-86
71. Blum DE, Ehsan T, Dungan D, Karis JP, Fisher RS (1998) Bilateral temporal hypometabolism in epilepsy. Epilepsia 39:651-659
72. Engel J Jr (1984) The use of positron emission tomographic scanning in epilepsy. Ann Neurol 15:S180-S191
73. Risinger MW, Engel J Jr, Van Ness PL, Henry TR (1989) Ictal localization of temporal lobe seizures with scalp/sphenoidal recordings. Neurology 39:1288-1293
74. Engel J Jr, Henry TR, Risinger MW, Mazziotta JC, Sutherling WW, Levesque MF, Phelps ME (1990) Presurgical evaluation for partial epilepsy: relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG. Neurology 40:1670-1677
75. Swartz BE, Theodore WH, Sanabria E, Fisher RS (1992) Positron emission and single photon emission computed tomographic studies in the frontal lobe with emphasis on the relationship to seizure foci. In: Chauvel P, Delgado-Escueta AV et al. (eds) Advances in neurology, vol 57. Raven, New York, pp 487-497
76. Barrington SF, Koutroumanidis M, Agathonikou A, Marsden PK, Binnie CD, Polkey CE, Maisey MN, Panayiotopoulos CP (1998) Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 39:753-766
77. Swartz BE, Halgren E, Delgado-Escueta AV, Mandelkern M, Gee M, Quinones N, Blahd WH, Repchan J (1989) Neuroimaging in patients with seizures of probable frontal lobe origin. Epilepsia 30:547-558
78. Henry TR, Mazziotta JC, Engel J Jr (1992) The functional anatomy of frontal lobe epilepsy studied with PET. In: Chauvel P, Delgado-Escueta AV et al (eds) Advances in neurology, vol 57. Raven, New York, pp 449-463
79. Duncan JS (1997) Imaging and epilepsy. Brain 120:339-377
80. Frost JJ, Mayberg HS, Fisher RS, Douglass KH, Dannals RF, Links JM, Wagner HN Jr (1988) Mu-opiate receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann Neurol 23:231-237
81. Savic I, Persson A, Roland P, Pauli S, Sedvall G, Widen L (1988) In-vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci. Lancet 8616:863-866
82. 123I-iododexetimide and SPECT in epilepsy. Ann Neurol 34:235-238
83. 11C]flumazenil positron emission tomography study. Epilepsia 38:1089-1097
84. 11C-flumazenil PET in neocortical epilepsy. Neurology 51:485-492
85. 11C]flumazenil binding after epilepsy surgery. Acta Neurol Scand 97:279-286
86. Cendes F, Caramanos Z, Andermann F, Dubeau F, Arnold DL (1997) Proton magnetic resonance spectroscopic imaging and magnetic resonance imaging volumetry in the lateralization of temporal lobe epilepsy: a series of 100 patients. Ann Neurol 42:737-746
87. Connelly A, Jackson GD, Duncan JS, King MD, Gadian DG (1994) Magnetic resonance spectroscopy in temporal lobe epilepsy. Neurology.44:1411-1417
88. Vermathen P, Ende G, Laxer KD, Knowlton RC, Matson GB, Weiner MW (1997) Hippocampal N-acetylaspartate in neocortical epilepsy and mesial temporal lobe epilepsy. Ann Neurol. 42:194-199
89. Woermann FG, McLean MA, Bartlett PA, Parker GJ, Duncan JS (1999) Short echo time single-voxel H-Magnetic resonance spectroscopy in magnetic resonance imaging-negative temporal lobe epilepsy: different biochemical profile compared with hippocampal sclerosis. Ann Neurol 45:369-376
90. Stanley JA, Cendes F, Dubeau F, Andermann F, Arnold DL (1998) Proton magnetic resonance spectroscopic imaging in patients with extratemporal epilepsy. Epilepsia 39:267-273
91. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH (1996) The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 39:95-99
92. 123I) iomazenil SPECT and GABA MRS. Epilepsia 40:1433-1438
93. Miller DH, Austin SJ, Connelly A, Youl BD, Gadian DG, McDonald WI (1991) Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet 337:58-59
94. Falini A, Calabrese G, Filippi M, Origgi D, Lipari S, Colombo B, Comi G, Scotti G (1998) Benign versus secondary-progressive multiple sclerosis: the potential role of 1H-MR spectroscopy in defining the nature of disability. Am J Neuroradiol 19:223-229
95. Barnes D, Munro PM, Youl BD, Prineas JW, McDonald WI (1991) The longstanding MS lesion; a quantitative MRI and electron microscopic study. Brain 114:1271-1280
96. Arnold DL, Wolinky JS, Matthews PM, Falini A (1998) The use of magnetic resonance spectroscopy in the evaluation of the natural history of MS. J Neurol Neurosurg Psychiatry 94:S94-S101
97. Davie CA, Hawkins CP, Barker GJ et al. (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117:49-58
98. Narayana PA, Doyle TJ, Lai D, Wolinsky JS (1998) Serial proton magnetic resonance spectroscopic imaging, contrast enhanced magnetic resonance imaging, and quantitative lesion volumetry in MS. Ann Neurol 43:56-71
99. De Stefano N, Matthews PM, Antel JP, Preul M, Francis G, Arnold DL (1996) Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 38:901-909